Middle East and Africa Urinary Tract Infection (UTI) Drugs Market Research Report Information by Drug Class (Quinolones, Aminoglycosides, β-lactam, Azoles and others), Clinical Indications (Urethritis, Cystitis, Pyelonephritis) and End User (Hospitals and Self-administered) - Forecast to 2030
ID: MRFR/Pharma/1900-HCR | 84 Pages | Author: Kinjoll Dey | November 2023
Table of Contents
1 Introduction
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power of Suppliers
4.1.2 Bargaining Power of Customer
4.1.3 Intensity of Competitor’s
4.1.4 Threat of New Entrants
5 Middle East and Africa UTI Drugs Market, by Drug Class
5.1 Introduction
5.1.1 Quinolones
5.1.2 Aminoglycosides
5.1.3 β-lactam
5.1.4 Azoles
5.1.5 Others
6 Middle East and Africa UTI Drugs Market, by Clinical Indications
6.1 Introduction
6.1.1 Urethritis
6.1.2 Cystitis
6.1.3 Pyelonephritis
7 Middle East and Africa UTI Drugs Market, by End User
7.1 Introduction
7.1.1 Hospitals
7.1.3 Self-administered
8 Middle East and Africa UTI Drugs Market, by Country
8.1 Introduction
8.2 UAE
8.3 Egypt
8.4 Saudi Arabia
8.5 Kuwait
8.6 Qatar
8.7 Oman
9 Company Landscape
9.1 Introduction
9.1.1 Mergers Acquisitions
9.1.2 Collaborations
9.1.3 Release/New Product Launches
9.1.4 Other (Expansion, Updates, Partnership)
10 Company Profile
10.1 Bayer AG
10.1.1 Company Overview
10.1.2 Product/Business Segment Overview
10.1.3 Financials
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Novartis AG
10.2.1 Overview
10.2.2 Product/Business Segment Overview
10.2.3 Financials
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Pfizer Inc.
10.3.1 Overview
10.3.2 Product/Business Segment Overview
10.3.3 Financials
10.3.4 Key Developments
10.3.5 SWOT Analysis
10.4 F. Hoffmann-La Roche Ltd
10.4.1 Overview
10.4.2 Product/Business Segment Overview
10.4.3 Financials
10.4.4 Key Developments
10.4.5 SWOT Analysis
10.5 AstraZeneca
10.5.1 Overview
10.5.2 Product/Business Segment Overview
10.5.3 Financials
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Cipla Inc.
10.6.1 Overview
10.6.2 Product/Business Segment Overview
10.6.3 Financials
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 Dr. Reddy’s Laboratories Ltd
10.7.1 Overview
10.7.2 Product/Business Segment Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Others
11 Appendix
List of Tables
TABLE 1 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, 2020-2027 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY CLINICAL INDICATIONS, 2020-2027 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)
List of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY DRUG CLASS
FIGURE 4 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY CLINICAL INDICATIONS
FIGURE 5 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY END USER
FIGURE 6 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY REGION
FIGURE 7 MIDDLE EAST AND AFRICA UTI DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
Leading companies partner with us for data-driven Insights.
